FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
Not All Black Women in the United States Have the Same Level of Risk for Triple-Negative Breast Cancer
We’ve known for a while that triple-negative breast cancer is more common in black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.
Explore Your Family Cancer History
Protect your health by learning more about your family’s history of cancer and other health problems. Then find out what you can do to help lower your risk. Get the tips.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
Population of US Cancer Survivors Grows to Nearly 17 Million
A new report by the American Cancer Society – in collaboration with the National Cancer Institute – estimates there are more than 16.9 million cancer survivors alive in the US today, and that number will grow to more than 22.1 million by 2030.
Breast Cancer Survivor Reaches Marathon Goals
Breast cancer survivor Fran Boyd is one of only 6,000 or so people worldwide to complete the World Majors, 6 of the biggest and most famous marathons.
Wish Dad a Healthy Father’s Day
Give the men in your life the best present this Father’s Day by sharing potentially lifesaving information about cancer screenings. Tell them about these 4 cancer tests.
Cancer Specialists Gather to Discuss Innovations in Research and Treatment
More than 39,000 cancer specialists from around the world are gathering in Chicago this week for the 55th annual meeting of the American Society of Clinical Oncology (ASCO).
